Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  WEE1 inhibitor AZD1775
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
WEE1 Inhibitor AZD1775, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UMCC 2013.094, NCI-2014-01214, HUM00079048, NCT01916551, NCT02037230
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9149, NCI-2013-01588, 130105, MPACT, P121047, 13-C-0105, NCT01827384
Gemcitabine Hydrochloride with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHL-093, NCI-2014-00620, NCI 9568, NCT02151292, 9568, NCT02101775
AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: D6010C00004, NCI-2015-00385, GYN 49, NCT02272790
Cisplatin with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: PHL-088, NCI-2014-00759, NCI 9416, NCT01935037, 9416, NCT02196168
A Phase II Trial of AZD1775 plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18304, NCI-2015-01598, 15.06.0034, 18304, NCT02513563
WEE1 Inhibitor AZD1775 with or without Cytarabine in Treating Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1488, NCI-2015-02136, NCT02666950
MK-1775 in Treating Patients with Refractory Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0032, NCI-2013-01568, 130032, NCI-2012-02991, P121045, 9350, NCT01748825
WEE1 Inhibitor AZD1775, Radiation Therapy, and Temozolomide in Treating Patients with Newly Diagnosed or Recurrent Glioblastoma Multiforme
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1202, NCI-2013-00858, NCT01849146
WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 37 months to 21 years
Trial IDs: ADVL1217, NCI-2013-01602, COG-ADVL1217, NCT01922076
Phase I Trial of AZD1775 and Belinostat in Treating Patients with Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9853, NCI-2015-00257, MCC-12-07328, NCI-9853, NCT02381548
AZD1775, Cisplatin, and Radiation Therapy in Treating Patients with Cervical Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHL-087, NCI-2013-01765, NCT01925326, 9407, NCT01958658
AZD1775, Docetaxel, and Cisplatin before Surgery in Treating Patients with Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9168, NCI-2015-01064, NCT02508246
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D6015C00001, NCI-2015-01525, REFMAL 383, NCT02482311
WEE1 Inhibitor AZD1775 with Radiation Therapy and Cisplatin in Treating Patients with Intermediate or High Risk Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1430, NCI-2016-00284, NCT02585973
WEE1 Inhibitor AZD1775 before Surgery in Treating Patients with Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0519, NCI-2016-00118, NCT02659241
Start Over